Abstract: AIM: To conduct a meta-analysis to evaluate the efficacy and safety of Xinmaining for cerebral infarction. METHODS: CBM, CNKI,WanFang Data, Cochrane Library, MEDLINE, EMbase were electronically searched for randomized controlled trials (RCTs) involving Xinmaining in the treatment for cerebral infarction. Meanwhile, all relevant Chinese and English literatures were retrieved by hand search. Stata 11.0 was used for Meta analysis.RESULTS: A total of twenty three randomized controlled trails involving 2737 patients were included . Clinical assessment measures were total response rates, neurological deficit scores, changes of hemorheology and blood lipids. The result of meta-analysis (twenty two trials) showed that there was significant difference on total response rates[RR=1.14,95%CI(1.11,1.18)]; Xinmaining group was superior to the control group in lowering WBLSV,WBHSV,plasma viscosity, HCT ,fibrinogen and WBRV; Xinmaining group showed better results in decreasing TC and TG and increasing HDL-C; Mild adverse effects were reported in only three patients of one trial.CONCLUSION: Current evidences showed that xinmaining could increase the total response rates, reduce the neurological deficit scores, decrease the hemodynamic indexes and improve the blood lipid parameters with a low incidence of adverse effects,which provides a good application prospect in clinical practice. However,the quality of current clinical trials was not high, more high-quality RCTs were needed to provide clear evidences for the efficacy and safety of Xinmaining for cerebral infarction.

Key words: Xinmaining, cerebral infarction, Meta-analysis